Hereditary Angioedema: Management Updates for the Specialty Pharmacist
This continuing education activity is supported by an educational grant from Takeda.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM TAKEDA.
FACULTY
Melanie B. Radi, PharmD, CSP
Manager, Clinical Programs Specialty Clinical Services
AllianceRx Walgreens Prime
Pittsburgh, Pennsylvania
At the completion of this activity, the participant will be able to:
- Characterize the diagnosis and background of hereditary angioedema (HAE) and the significance of early intervention
- Examine the clinical data of FDA-approved agents and emerging therapies for acute treatment and prophylaxis of HAE
- Explore the need for individualized treatment and the role of the specialty pharmacist in patient education for effective HAE management
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: May 15, 2020
EXPIRATION DATE: May 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at
Articles in this issue
about 5 years ago
Article
Emerging Strategies in the Treatment and Management of Idiopathic Pulmonary Fibrosisabout 5 years ago
Article
Hereditary Angioedema: Only Appropriate Pharmacotherapy Reduces Overall Costsabout 5 years ago
Article
Specialty Pharmacists Have Broad Responsibilities in Chronic Lymphocytic Leukemiaabout 5 years ago
Article
New Agents for Myelodysplastic Syndromes May Reduce Transfusion RequirementsNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Advise Patients About Self-Care Measures to Treat Mild to Moderate GI IssuesSeptember 18th 2025
Evaluation of Pharmacist-Driven Penicillin Allergy ReconciliationSeptember 17th 2025
Pharmacists Can Apply Their Expertise to the Medical Psilocybin ActSeptember 16th 2025
From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy ResearchSeptember 15th 2025
